The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
Philipp Ziegler,
Andreas D. Hartkopf,
Markus Wallwiener,
Lothar Häberle,
Hans-Christian Kolberg,
Peyman Hadji,
Hans Tesch,
Johannes Ettl,
Diana Lüftner,
Volkmar Müller,
Laura L. Michel,
Erik Belleville,
Pauline Wimberger,
Carsten Hielscher,
Hanna Huebner,
Sabrina Uhrig,
Lena A. Wurmthaler,
Carolin C. Hack,
Christoph Mundhenke,
Christian Kurbacher,
Peter A. Fasching,
Rachel Wuerstlein,
Michael Untch,
Wolfgang Janni,
Florin-Andrei Taran,
Michael P. Lux,
Diethelm Wallwiener,
Sara Y. Brucker,
Tanja N. Fehm,
Andreas Schneeweiss,
Chloë Goossens
Affiliations
Philipp Ziegler
Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN)
Andreas D. Hartkopf
Department of Obstetrics and Gynecology, University of Tübingen
Markus Wallwiener
Department of Gynecology, Halle University Hospital
Lothar Häberle
Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN)
Hans-Christian Kolberg
Department of Gynecology and Obstetrics, Marienhospital Bottrop
Peyman Hadji
Frankfurt Center for Bone Health
Hans Tesch
Oncology Practice, Bethanien Hospital
Johannes Ettl
Department of Obstetrics and Gynecology, Klinikum Rechts Der Isar, Technical University of Munich
Diana Lüftner
Immanuel Hospital Märkische Schweiz & Immanuel Campus Rüdersdorf, Medical University of Brandenburg Theodor-Fontane
Volkmar Müller
Department of Gynecology, Hamburg-Eppendorf University Medical Center
Laura L. Michel
National Center for Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg University Hospital
Erik Belleville
ClinSol GmbH & Co KG
Pauline Wimberger
National Center for Tumor Diseases Dresden and Department of Gynecology and Obstetrics, University Hospital Dresden, TU Dresden
Carsten Hielscher
g.SUND Gynäkologie-Onkologisches Zentrum
Hanna Huebner
Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN)
Sabrina Uhrig
Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN)
Lena A. Wurmthaler
Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN)
Carolin C. Hack
Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN)
Christoph Mundhenke
Department of Gynecology and Obstetrics, Klinik Hohe Warte
Christian Kurbacher
Department of Gynecology I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz
Peter A. Fasching
Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN)
Rachel Wuerstlein
Department of Gynecology and Obstetrics, Breast Center and CCC Munich, University Hospital LMU Munich
Michael Untch
Department of Gynecology and Obstetrics, Helios Clinics Berlin-Buch
Wolfgang Janni
Department of Gynecology and Obstetrics, Ulm University Hospital
Florin-Andrei Taran
Department of Obstetrics and Gynecology, University Medical Center Freiburg
Michael P. Lux
Department of Gynecology and Obstetrics, Frauenklinik St. LouiseSt. Josefs-KrankenhausVincenz Kliniken Salzkotten + Paderborn
Diethelm Wallwiener
Department of Obstetrics and Gynecology, University of Tübingen
Sara Y. Brucker
Department of Obstetrics and Gynecology, University of Tübingen
Tanja N. Fehm
Department of Gynecology and Obstetrics, Düsseldorf University Hospital
Andreas Schneeweiss
National Center for Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg University Hospital
Chloë Goossens
Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN)
Abstract Background Although adequate physical activity has been shown to be beneficial in early breast cancer, evidence in metastatic breast cancer is sparse and contradictory, which could be related to distinct effects of physical activity on the different molecular cancer subtypes. Therefore, we here evaluated the effect of physical activity on progression-free and overall survival (PFS, OS) in metastatic breast cancer, specifically looking at molecular subtypes. Methods International Physical Activity Questionnaire (IPAQ) questionnaires, filled out by patients enrolled in the prospective PRAEGNANT registry (NCT02338167; n = 1,270) were used to calculate metabolic equivalent task (MET) minutes, which were subsequently categorized into low (n = 138), moderate (n = 995) or high IPAQ categories (n = 137). Cox regression analyses were used to evaluate the impact of IPAQ categories and its interaction with molecular subtypes on PFS and OS. Results Patient and tumor characteristics were equally distributed across IPAQ categories. HER2pos, HRpos and TNBC were present in 23.1%, 65.7% and 11.2% of patients, respectively. IPAQ scores did not have an impact on PFS and OS in addition to established prognostic factors, either overall or in particular molecular subtypes (PFS: p = 0.33 and OS: p = 0.08, likelihood ratio test). Exploratory analyses showed higher overall survival rates for high IPAQ categories compared to low/moderate IPAQ categories in luminal B-like breast cancer. Conclusions Self-reported physical activity using the IPAQ questionnaire did not significantly affect PFS or OS in patients suffering from metastatic breast cancer. Nevertheless, some hypothesis-generating differences between molecular subtypes could be observed, which may be interesting to evaluate further.